Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours

Expert Opinion on Biological Therapy

Volumn 5, Issue 12, 2005, Pages 1557-1569

  Cegnar, Mateja ^a   Kristl, Julijana ^a   Kos, Janko ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cancer; Drug delivery; Nanoparticles; Polymer; Targeting

Indexed keywords

ACRYLIC ACID DERIVATIVE; ADJUVANT; ANTINEOPLASTIC AGENT; APTAMER; CANCER ANTIBODY; CISPLATIN; CYTOTOXIC AGENT; DACTINOMYCIN; DENDRIMER; DEXTRIN; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; MACROGOL; MELPHALAN; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; NANOPARTICLE; OLIGONUCLEOTIDE; PACLITAXEL; POLYAMIDOAMINE; POLYETHYLENEIMINE; POLYMER; POLYSACCHARIDE; POLYSTYRENE DERIVATIVE; POLYSTYRENE MALEIC ANHYDRIDE COPOLYMER; POVIDONE; RICINOMACROGOL; SMALL INTERFERING RNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

CANCER THERAPY; CARDIOTOXICITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG RELEASE; DRUG STABILITY; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PHAGOCYTE; PHAGOCYTOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; TUMOR; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY; NEOPLASMS; POLYMERS;

EID: 28844460729     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.12.1557     Document Type: Review

References (85)

1. FRANKS LM: What is cancer? In: Introduction to the Cellular and Molecular Biology of Cancer. Franks LM, Teich NM (Eds), Oxford University Press, London (1997):1-20.
2. HART IR: The spread of tumours. In: Introduction to the Cellular and Molecular Biology of Cancer. Franks LM, Teich NM (Eds), Oxford University Press, London (1997):21-33.
3. BRIGGER I, DUBERNET C, COUVREUR P: Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. (2002) 54:631-651.
4. DUNCAN R: Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as common gateway? Pharm. Sci. Technol. Today (1999) 2(11):441-449.
5. BABAN DF, SEYMOUR LW: Control of tumour vascular permeability. Adv. Drug Deliv. Rev. (1998) 34(1):109-119.
6. OGRIS M, WAGNER E: Targeting tumours with non-viral gene delivery systems. Drug Discov. Today (2002) 7(8):479-485.
7. BRANNON-PEPPAS L, BLANCHETTE JO: Nanoparticles and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. (2004) 56:1649-1659. This paper describes the possibilities of using NPs in the treatment of cancer.
8. FENG S, CHIEN S: Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other disease. Chem. Engin. Sci. (2003) 58(18):4087-4114.
9. GELDERBLOM H, VERWEIJ J, NOOTER K, SPARREBOOM A: Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer (2001) 7:1590-1598.
10. SINGLA AK, GARG A, AGGARWAL D: Paclitaxel and its formulations. Int. J. Pharm. (2002) 235:179-192.
11. STOUCH TR, GUDMUNDSSON O: Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev. (2002) 54:315-328.
12. TORCHILIN VP, LUKYANOV AN: Peptide and protein drug delivery to and into tumours: challenges and solutions. Drug Discov. Today (2003) 8(6):259-266.
13. HANS ML, LOWMAN AM: Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. (2002) 6:319-327.
14. PANYAM J, LABHASETWAR V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. (2003) 55:329-347.
15. SONG CX, LABHASETWAR V, MURPHY H et al.: Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J. Control. Rel. (1997) 43:197-212.
16. JUNG T, KAMM W, BREITENBACH A, KAISERLING E, XIAO JX, KISSEL T: Biodegradible nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. (2000) 50:147-160.
17. MCCLEAN S, PROSSER E, MEEHAN E et al.: Binding and uptake of biodegradible poly-DL-lactide micro- and nanoparticles in intestinal epithelia. Eur. J. Pharm. Sci. (1998) 6:153-163.
18. PRABHA S, ZHOU WZ, PANYAM J, LABHASETWAR V: Size-dependancy of nanoparticle-mediated gene transfection: studies with fractionated nanoparticle. Int. J. Pharm. (2002) 244:105-115.
19. DESAI MP, LABHASETWAR V, AMIDON GL, LEVY RJ: Gastrointestinal uptake of biodegradible microparticles: effect of particle size. Pharm. Res. (1996) 13:1838-1845.
20. YIN WIN K, FENG S-S: Effect of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials (2005) 26:2713-2711.
21. MAEDA H, MATSUMURA Y: Tumouritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. (1989) 6:193-210.
22. YUAN F, DELLIAN M, FUKUMURA D et al.: Vascular permeability in a human tumour xenograft: molecular size dependance and cutoff size. Cancer Res. (1995) 55:3752-3756.
23. DUNCAN R: The dawning era of polymer therapeutics. Nature Rev. (2003) 2:347-360. An interesting review that discusses the application of polymer therapeutics.
24. SALTZMAN WM, FUNG LK: Polymeric implants for cancer therapy and diagnosis. Adv. Drug Deliv. Rev. (1997) 26:209-230.
25. JAIN JP, MODI S, DOMB AJ, KUMAR N: Role of polyanhidrides as localized drug carriers. J. Control. Release (2005) 103(3):541-563.
26. SINHA VR, TREHAN A: Biodegradable microspheres for protein delivery. J. Control. Release (2003) 90:261-280.
27. WHITTLESEY KJ, SHEA LD: Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface. Exp. Neurol. (2004) 190:1-16.
28. LI C: Poly(L-glutamic acid)-anticancer drug conjugates. Adv. Drug Deliv. Rev. (2002) 54:695-713.
29. SAHOO SK, LABHASETWAR V: Nanotech approach to drug delivery and imaging. Drug Discov. Today (2003) 8(24):1112-1120.
30. WHITE NS, ERRINGTON RJ. Fluorescence techniques for drug delivery research: theory and practice. Adv. Drug Deliv. Rev. (2005) 57(1,2):17-42.
31. QUINTANAR-GUERRERO D, ALLEMANN E, FESSI H et al.: Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymes. Drug Dev. Ind. Pharm. (1998) 24(12):1113-1128.
32. ALLEMANN E, GURNY R, DOELKER E: Drug-loaded nanoparticles - preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. (1993) 39(5):173-191.
33. VAUTHIER-HOLTZSCHERER C, BENABBOU S, SPENLEHAUER G et al.: Methodology for the preparation of ultra-dispersed polymer systems. STP Pharm. Sci. (1991) 1(2):109-116.
34. KREUTER J: Nanoparticles. In: Encyclopedia of Pharmaceuticcal Technology. Swarbrick J, Boylan JC (Eds.), Marcel Dekker, New York-Basel-Hong Kong (1994):165-190.
35. GRAVES M: Stem cells, haematopoiesis, and leukaemia. In: Introduction to the Cellular and Molecular Biology of Cancer. Franks LM, Teich NM (Eds.), Oxford University Press, London (1997):251-263.
36. BARRAUD L, MERLE P, SOMA E et al.: Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. (2005) 42(5):736-743.
37. SHARMA D, CHELVI TP, KAUR J et al.: Novel taxol formulation: polyvinylpyrrolidine nanoparticles-encapsulated taxol for drug delivery in cancer therapy. Oncol. Res. (1996) 8:281-286.
38. MITRA S, GAUR U, GOSH PC, MAITRA AN: Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Release (2001) 74:317-323.
39. OTSUKA H, NAGASAKI Y, KATAOKA K: PEGylated nanoparticles for biological and pharmaceutical application. Adv. Drug Deliv. Rev. (2003) 55:403-419.
40. MACHIDA Y, ONISHI H, KATO Y, MACHIDA Y: Efficacy of nanoparticles containing irinotecan prepared using poly(DL-lactic acid) and poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) against M5076 tumour in the early liver metastatic stage. STP Pharm. Sci. (2003) 13(4):225-230.
41. KRISTL J, ALLEMANN E, GURNY R: Formulation and evaluation of zinc-phthalocyanine loaded poly(D,L-lactic acid) nanoparticles. Acta Pharm. (1996) 46:1-12.
42. LE GAREC D, GORI S, KARKAN D et al.: Preparation, characterisation, cytotoxicity and biodistribution of docetaxel-loaded polymeric micelle formulations. J. Drug Deliv. Sci. Tec. (2005) 15(2):115-120.
43. KAKIZAWA Y, KATAOKA K: Block copolymer micelles for delivery of gene and related compounds. Adv. Drug Deliv. Rev. (2002) 54:203-222.
44. RÖSLER A, VANDERMEULEN GWM, KLOK HA: Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv. Drug Deliv. Rev. (2001) 53:95-108. This is a review article on block copolymers.
45. KANG N, PERRON ME, PRUD'HOMME RE, ZHANG YB, GAUCHER G, LEROUX JC: Stereocomplex block copolymer micelles: core-shell nanostructures with enhanced stability. Nano Letters (2005) 5(2):315-319.
46. BOAS U, HEEGAARD PM: Dendrimers in drug research. Chem. Soc. Rev. (2004) 33:43-63.
47. GILLES ER, FRECHET MJ: Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today (2005) 10(1):35-43.
48. ULBRICH K, ŠUBR V: Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Deliv. Rev. (2004) 56:1023-1050.
49. ZHANG S, XU Y, WANG B, QIAO W, LIU D, LI Z: Cationic compounds used in lipoplexes and polyplexes for gene delivery. J. Control. Rel. (2004) 100(2):165-180.
50. SCHMIDT-WOLF GD, SCHMIDT-WOLF IG: Non-viral and hybrid vectors in human gene therapy: an update. Trends Mol. Med. (2003) 9(2):67-71.
51. RUBANYI GM: The future of human gene therapy. Mol. Asp. Med. (2001) 22:113-142.
52. EL-ANEED A: An overview of current delivery systems in cancer gene therapy. J. Control. Release (2004) 94:1-14.
53. CROMMELIN DJ, STORM G, JISKOOT W, STENEKES R, MASTROBATTISTA E, HENNINK WE: Nanotechnological approaches for the delivery of macromolecules. J. Control. Release (2003) 87:81-88.
54. MARCUCCI F, LEFOULON F: Active targeting with particulate drug carriers in tumour therapy: fundamentals and recent progress. Drug Discov. Today (2004) 9(5):219-228.
55. DUNCAN R, CABLE HC, LLOYD JB, REJMANOVA P, KOPECEK J: Polymers containing enzymically degradable bond. Design of oligopeptide side-chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Macromol. Chem. (1983) 184:1997-2008.
56. KOS J, LAH T: Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer. Oncol. Rep. (1998) 5:1349-1361.
57. HUANG Y, GHANDEHARI H, DUAN YR, ZHANG ZR: HPMA copolymer-mitoxantrone conjugates for targeted cancer chemotherapy. J. Drug Deliv. Sci. Tech. (2004) 14(3):187-191.
58. VINOGRADOV S: The second annual symposium on nanomedicine and drug delivery: exploring recent developments and assessing major advances. Expert Opin. Drug Deliv. (2004) 1:181-184.
59. KATAOKA K, MATSUMOTO T, YOKOYAMA M et al.: Doxorubicin-loaded poly(ethylene glycol)-poly(β-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J. Control. Release (2000) 64:143-153.
60. THORPE PE, WAWRZYNCZAK EJ, BURROWS FJ: Monoclonal antibodies and therapy. In: Introduction to the Cellular and Molecular Biology of Cancer. Franks LM, Teich NM (Eds.), Oxford University Press, London (1997):353-379.
61. HUDSON PJ, SOURIAN C: Engineered antibodies. Nat. Med. (2003) 9:129-134.
62. TANAKA T, SHIRAMOTO S, MIYASHITA M, FUJISHIMA Y, KANEO Y: Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. J. Pharm. (2004) 277:39-61.
63. NORI A, KOPECEK J: Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Deliv. Rev. (2004) 57(4):609-636. This paper presents modifications of polymeric NPs to trigger intracellular vesicles and targets.
64. GABOR F, WIRTH M: Lectin-mediated drug delivery: fundamentals and perspectives. STP Pharm. Sci. (2003) 13(1):3-16.
65. BRODSKY FM: New fashions in vesicle coats Trends Cell Biol. (1997) 7:175-179.
66. FONSECA S, SIMOES S, GASPAR R: Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterisation and in vitro anti-tumural activity. J. Control. Release (2002) 83:273-286.
67. CEGNAR M, KOS J, KRISTL J: Cystatin incorporated in poly(lactide-co- glycolide) nanoparticles: development and fundamental studies on preservation of its activity. Eur. J. Pharm. Sci. (2004) 22(5):357-364.
68. RUEFLI AA, JOHNSTONE RW: A role for P-glycoprotein in regulating cell growth and survival. Clin. Appl. Immunol. Rev. (2003) 4:31-47.
69. MINKO T, BATRAKOVA EV, LI S et al.: Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J. Control. Release (2005) 105:269-278.
70. KABANOV AV, BATRAKOVA EV, ALAKHOV VY: Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. (2002) 54:759-779.
71. OWENS J: Stealthy polymers target drug-resistant tumour cells. Drug Discov. Today (2001) 6(11):551-552.
72. MINKO T, KOPECKOVA P, KOPECEK J: Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J. Control. Release (1999) 59:133-148.
73. DEBATIN KM: Apoptosis pathways in cancer and cancer therapy. Cancer Immunol. Immunother. (2004) 53:153-159.
74. NISHIYAMA N, NORI A, MALUGIN A, KASUYA Y, KOPECKOVA P, KOPECEK J: Free and N-(2-hydroxypropyl) methacrylamide copolymer-bound geldanamycin derivate induce different stress responses in A2780 human ovarian carcinoma cells. Cancer Res. (2003) 63:7876-7882.
75. TURK V, KOS J, TURK B: Cysteine cathepsins (proteases) - On the main stage of cancer? Cancer Cell (2004) 5:409-410.
76. PREMZL A, ZAVAŠNIK-BERGANT V, TURK V, KOS J: Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp. Cell Res. (2003) 283(2):206-214.
77. CEGNAR M, PREMZL A, ZAVAŠNIK-BERGANT V, KRISTL J, KOS J: Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumour cells. Exp. Cell Res. (2004)301:223-231. This paper showed an effective inhibition of intracellular proteases using delivery of inhibitor by polymer NPs.
78. DEGOUT A, LABEUR C, GOETHALS M, BRASSEUR R, VANDEKERCKHOVE J, ROSSENEU M: Enhanced efficiency of a targeted fusogenic peptide. Biochimica Biophysica Acta - Biomembranes (1998) 1372:102-116.
79. LUNGWITZ U, BREUNIG M, BLUNK T, GÖPFERICH A: Polyethylenimine-based non-viral gene delivery. Eur. J. Pharm. Biopharm. (2005) 60(2):247-266.
80. DESHAYES S, MORRIS MC, DIVITA G, HEITZ F: Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol. Life Sci. (2005) 62:1839-1849.
81. MERDAN T, KOPECEK J, KISSEL T: Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. (2002) 54:715-758. This article summarises efforts on the application of polyplexes in cancer therapy.
82. SINHA VR, GOYEL V, TREHAN A: Radioactive microspheres in therapeutics. Pharmazie (2003) 59:419-426.
83. BARTH RF, CODERRE JA, VICENTE MG, BLUE TE: Boron neutron capture therapy of cancer: current status and future prospects. Clin. Cancer Res. (2005) 11:3987-4002. This article presents the current status and future prospects of boron neutron capture therapy of cancer.
84. NOVAK-DESPOT D, KOS J, SERŠA G, CEMAŽAR M, ŠKRK J, GUBENŠEK F: Boronated CDI315B monoclonal antibody and its potential use in boron neutron capture therapy. In: Advances in Neutron Capture Therapy (Volume II), Chemistry and Biology. Larsen BB, Crawford J, Weinreich R (Eds.), Elsevier Science, Amsterdam, The Netherlands (1997):516-518.
85. HUANG SM, BOCK JM, HARARI PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of head and neck. Cancer Res. (1999) 59:1935-1940.